Daré Bioscience (NASDAQ:DARE) Shares Cross Above Fifty Day Moving Average – Here’s Why

Shares of Daré Bioscience, Inc. (NASDAQ:DARE) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.36 and traded as high as $3.38. Daré Bioscience shares last traded at $3.33, with a volume of 49,228 shares changing hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Daré Bioscience in a research report on Tuesday, December 17th.

Daré Bioscience Stock Performance

The company has a market capitalization of $28.97 million, a price-to-earnings ratio of -5.64 and a beta of 1.28. The company has a 50-day moving average price of $3.34 and a 200-day moving average price of $3.43.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its position in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors and hedge funds.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.